Share
1,216 Posts.
lightbulb Created with Sketch. 843
clock Created with Sketch. 30/06/23
09:23
Share
Originally posted by Watmighthavben:
↑
Her Vaxx has often been viewed as a comparable if not better drug than Roche's Herceptin, given not only its outstanding overall survival rates (OSR) but it's strong safety parameters. With peak sales of approximately $6 billion USD Herceptin may well have been worth close to $25 billion USD to the Roche pharmaceutical company. That's a value equivalent in excess of $5 per IMU share when taking Imugene's current market cap and shares on offer into consideration. Yes the HER 2 market is a more competitive space than when Herceptin first arrived and reached peak sales, but it shows how completely ridiculous the IMU share price is at these levels.
Expand
Hervaxx is on the way to blowing Herceptin out of the water in terms of Overall survival, safety profile and with a cheaper cost allowing it to be accessed by most of the humans on this planet . This magnificent management team has also obtained patents all over the world and how's this for another advantage , Hervaxx's IP doesn't run out till late in the 2030's , Herceptin has only got a couple of years to go
(20min delay)